These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

518 related articles for article (PubMed ID: 25146407)

  • 21. Survival and prognostic factors in systemic sclerosis-associated pulmonary hypertension: a systematic review and meta-analysis.
    Lefèvre G; Dauchet L; Hachulla E; Montani D; Sobanski V; Lambert M; Hatron PY; Humbert M; Launay D
    Arthritis Rheum; 2013 Sep; 65(9):2412-23. PubMed ID: 23740572
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nailfold capillary density is associated with the presence and severity of pulmonary arterial hypertension in systemic sclerosis.
    Hofstee HM; Vonk Noordegraaf A; Voskuyl AE; Dijkmans BA; Postmus PE; Smulders YM; Serné EH
    Ann Rheum Dis; 2009 Feb; 68(2):191-5. PubMed ID: 18375538
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS): baseline characteristics and description of study population.
    Hinchcliff M; Fischer A; Schiopu E; Steen VD;
    J Rheumatol; 2011 Oct; 38(10):2172-9. PubMed ID: 21844142
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relation of novel echocardiographic measures to invasive hemodynamic assessment in scleroderma-associated pulmonary arterial hypertension.
    Gopal DM; Doldt B; Finch K; Simms RW; Farber HW; Gokce N
    Arthritis Care Res (Hoboken); 2014 Sep; 66(9):1386-94. PubMed ID: 24515598
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictive value of isolated DLCO reduction in systemic sclerosis patients without cardio-pulmonary involvement at baseline.
    Colaci M; Giuggioli D; Sebastiani M; Manfredi A; Lumetti F; Luppi F; Cerri S; Ferri C
    Reumatismo; 2015 Dec; 67(4):149-55. PubMed ID: 27215180
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Limitations to the 6-minute walk test in interstitial lung disease and pulmonary hypertension in scleroderma.
    Garin MC; Highland KB; Silver RM; Strange C
    J Rheumatol; 2009 Feb; 36(2):330-6. PubMed ID: 19208563
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Isolated DLco/VA reduction in systemic sclerosis patients: a new patient subset?
    Corzo P; Pros A; Martinez-Llorens J; Molina L; Ling SF; Balcells E
    Clin Rheumatol; 2018 Dec; 37(12):3365-3371. PubMed ID: 30368639
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registry.
    Chung L; Domsic RT; Lingala B; Alkassab F; Bolster M; Csuka ME; Derk C; Fischer A; Frech T; Furst DE; Gomberg-Maitland M; Hinchcliff M; Hsu V; Hummers LK; Khanna D; Medsger TA; Molitor JA; Preston IR; Schiopu E; Shapiro L; Silver R; Simms R; Varga J; Gordon JK; Steen VD
    Arthritis Care Res (Hoboken); 2014 Mar; 66(3):489-95. PubMed ID: 23983198
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical and laboratory characteristics of systemic sclerosis patients with pulmonary arterial hypertension in China.
    Huang J; Li M; Tian Z; Hsieh E; Wang Q; Liu Y; Xu D; Hou Y; Zhao J; Guo X; Lai J; Hu C; Song N; Sun Q; Sun Q; Zhang F; Zhao Y; Zeng X
    Clin Exp Rheumatol; 2014; 32(6 Suppl 86):S-115-21. PubMed ID: 25372797
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lysyl oxidase-a possible role in systemic sclerosis-associated pulmonary hypertension: a multicentre study.
    Vadasz Z; Balbir Gurman A; Meroni P; Farge D; Levi Y; Ingegnoli F; Braun-Moscovici Y; Rosner I; Slobodin G; Rozenbaum M; Jiries N; Kaly L; Boulman N; Zilber K; Ginsberg S; Awisat A; Goldberg Y; Lurie M; Ghigna MR; Guignabert C; Humbert M; Rimar D
    Rheumatology (Oxford); 2019 Sep; 58(9):1547-1555. PubMed ID: 30770717
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Haemodynamics and serial risk assessment in systemic sclerosis associated pulmonary arterial hypertension.
    Weatherald J; Boucly A; Launay D; Cottin V; Prévot G; Bourlier D; Dauphin C; Chaouat A; Savale L; Jaïs X; Jevnikar M; Traclet J; De Groote P; Simonneau G; Hachulla E; Mouthon L; Montani D; Humbert M; Sitbon O
    Eur Respir J; 2018 Oct; 52(4):. PubMed ID: 30209196
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased expression of growth differentiation factor-15 in systemic sclerosis-associated pulmonary arterial hypertension.
    Meadows CA; Risbano MG; Zhang L; Geraci MW; Tuder RM; Collier DH; Bull TM
    Chest; 2011 May; 139(5):994-1002. PubMed ID: 20829333
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ventilation distribution as a contributor to the functional exercise capacity in patients with systemic sclerosis-associated interstitial lung disease without pulmonary hypertension.
    Andrade FM; Oliveira AD; Lopes AJ
    Braz J Med Biol Res; 2019; 52(8):e8513. PubMed ID: 31365695
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevalence and clinical importance of gastroesophageal reflux in Chinese patients with systemic sclerosis.
    Liu X; Li M; Xu D; Hou Y; Wang Q; Tian Z; Sun Q; Zeng X
    Clin Exp Rheumatol; 2012; 30(2 Suppl 71):S60-6. PubMed ID: 22691211
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype.
    Chung L; Liu J; Parsons L; Hassoun PM; McGoon M; Badesch DB; Miller DP; Nicolls MR; Zamanian RT
    Chest; 2010 Dec; 138(6):1383-94. PubMed ID: 20507945
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study.
    Coghlan JG; Denton CP; Grünig E; Bonderman D; Distler O; Khanna D; Müller-Ladner U; Pope JE; Vonk MC; Doelberg M; Chadha-Boreham H; Heinzl H; Rosenberg DM; McLaughlin VV; Seibold JR;
    Ann Rheum Dis; 2014 Jul; 73(7):1340-9. PubMed ID: 23687283
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A prospective, longitudinal study evaluating the baseline six-minute walk test as an individual reference value in systemic sclerosis patients.
    Vandecasteele E; Melsens K; De Keyser F; De Pauw M; Deschepper E; Decuman S; Piette Y; Thevissen K; Brusselle G; Smith V
    Clin Exp Rheumatol; 2018; 36 Suppl 113(4):95-101. PubMed ID: 30183593
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Survival in systemic sclerosis with pulmonary arterial hypertension has not improved in the modern era.
    Rubenfire M; Huffman MD; Krishnan S; Seibold JR; Schiopu E; McLaughlin VV
    Chest; 2013 Oct; 144(4):1282-1290. PubMed ID: 23744060
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relevance of partitioning DLCO to detect pulmonary hypertension in systemic sclerosis.
    Sivova N; Launay D; Wémeau-Stervinou L; De Groote P; Remy-Jardin M; Denis G; Lambert M; Lamblin N; Morell-Dubois S; Fertin M; Lefevre G; Sobanski V; Le Rouzic O; Hatron PY; Wallaert B; Hachulla E; Perez T
    PLoS One; 2013; 8(10):e78001. PubMed ID: 24205063
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Severity of systemic sclerosis-associated pulmonary arterial hypertension in African Americans.
    Blanco I; Mathai S; Shafiq M; Boyce D; M Kolb T; Chami H; K Hummers L; Housten T; Chaisson N; L Zaiman A; M Wigley F; J Tedford R; A Kass D; Damico R; E Girgis R; M Hassoun P
    Medicine (Baltimore); 2014 Jul; 93(5):177-185. PubMed ID: 25181310
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.